GHP April 2017

GHP / April 2017 7 NEWS , The agreement with SEHA, the corporate marketing name of the Abu Dhabi Health Services Company, will give Crawford access to 12 public hospitals and more than five million patients annually as it looks to expand its offering into the wider United Arab Emirates (UAE). 2015 figures published by The World Bank highlight the Middle East as an area of high diabetes prevalence, with almost one in five (19.3%) people aged 29-79 living with the disease in the UAE. That figure is 8.5% higher than in the United States, where the risk of amputations related to infected diabetic foot ulcers is also ex- tremely high. Alongside the SEHA contract listing, Crawford has also an- nounced plans to build its sales presence in Saudi Arabia having agreed a partnership with a new localised distributor. Chris Lane, Crawford health- care’s director of strategy com- mented: “Increasing levels of di- abetes and an ageing population are both global concerns, and key issues that are informing our international growth story. Our technology-led dressings, devel- oped by our in-house team, are making a real impact on group sales in our existing markets, and we’ve every confidence we can replicate those results in the Mid- dle East.” Cheshire-based Crawford, which was recognised in 2016 with the Queen’s Award for Enterprise in International Trade for its success exporting to the Americas and Europe, recently signed a similar agreement in the US with leading group purchasing organisation, Premier Inc. SEHA’s Senior Charge Nurse (Medical & Surgical), Gulnaz Tariq Mir, added: “Chronic wounds are clearly a major issue in the Middle East, and a treatment category we expect will continue to grow in the coming years. The ad- vanced R&D behind Crawford’s dressings, as well as their prov- en success across a number of international markets with similar demographics, made them an ideal choice as we continue to pursue improvements in patient outcomes.” www.crawfordhealthcare.com people affected by asthma, the ‘Get it Right’ campaign also aims to foster further dialogue between people affected by asthma and their physicians. The campaign: • Encourages people affect- ed by asthma to spread the message on social media of ‘Get it Right’ when using asth- ma inhalers with the dedicat- ed hashtag #Getitright and #worldasthmaday • Invites healthcare profession- als to join a livestream broad- cast on 6 June, 2017 on the ‘dos / don’ts’ of inhaler tech- nique (http://letstalkrespirato- ry.eu/inhalationtechnology ). Entitled ‘Breathing New Life Into Inhalation Technology – Inside Out, An Exploration of Inhalers’, the webinar will be chaired by Prof. Dr. J. Chris- tian Virchow, Head of Depart- ment of Pneumology, Univer- sity of Rostock, Germany, and aims to support health- care professionals in helping people affected by asthma. EFA President (European Fed- eration of Allergy and Airways Diseases Patients’ Association), Mikaela Odemyr said: “Following the findings of EFA’s HEY YA re- port (3) about how young asthma patients face their disease and treatment, addressing adherence to asthma treatment, correct tech- nique and tailored support from friends, family and healthcare professionals is crucial for people with asthma.” “Teva is committed to delivering new, innovative solutions to sup- port the asthma community,” said Janice Canvin, senior medical di- rector, Teva Respiratory. “Ongo- ing education is of paramount im- portance in chronic diseases like asthma. This campaign enables patients to participate and have a more effective role in their own treatment, working together with their clinician to achieve optimal inhaler use and disease control.” Asthma is a chronic (long term) disease usually characterised by airway inflammation and narrow- ing of the airways, which can vary over time. The World Health Or- ganization (WHO) estimates 235 million people suffer from asthma worldwide (4). In Europe, almost Crawford Healthcare Secure Government Tender to Fuel Middle East Expansion 30 million children and adults un- der the age of 45 have asthma, with six million of them having se- vere symptoms. Approximately, one third of Europeans will devel- op asthma at some time, mostly before the age of 20.5. In the UK alone, there are 5.4 million people with asthma, which means asth- ma affects one in every 11 peo- ple in the UK and one in five UK households. (6) (1). Price DE., et al. Assessment of potential important device er- rors performed by asthma pa- tients in the global iHARP review service. Abstract presented at: 7th World Conference of the In- ternational Primary Care Respira- tory Group; Diagnostic Device Session 2. 24 May 2014. Abstract number: OR-100. (2). Price DB., et al. Inhaler er- rors in the CRITIKAL study: type, frequency, and association with asthma outcomes. 2017. J Aller- gy Clin Immunol Pract. S2213- 2198(17)30007-7. doi: 10.1016/j. jaip.2017.01.004. [Epub ahead of print] (3). De Vocht, Joke, et al. Hey Ya! Health Literacy, Young Patients with Asthma and Adherence to treatment: EFA Report and Eu- ropean Recommendations. Eu- ropean Federation of Allergy and Airways Diseases Patients’ Asso- ciations, 2015 (4). Chronic respiratory diseases: asthma. WHO website. Available at: http://www.who.int/respiratory/ asthma/en/. [Last accessed: 6 April 2017.] (5). The European Federation of Allergy and Airways Diseas- es (EFA) Patients’ Association, ‘Inform, Prevent, Care, Involve’ Leaflet, 2014, EFA website: Avail- able at http://www.efanet.org/im- ages/2014/06/EFA-Leaflet_2014. pdf [Last accessed: 10 April 2017. (6). Asthma UK, ‘Asthma Facts & Statistics’, Asthma UK web- site: Available at https://www. asthma.org.uk/about/media/ facts-and-statistics/ [Last ac- cessed: 10 April 2017.] For more information, visit www. tevapharm.com Crawford Healthcare, the UK’s fastest growing advanced wound care company, has won a key government tender that will see its innovative wound dressings recommended as products of choice by Abu Dhabi’s public health body.